Kyowa Kirin Goes Global With MEI’s PI3K Contender In $683m Deal
Executive Summary
Japanese firm builds on existing alliance to gain most global rights to US company’s potential best-in-class drug for lymphoma and B-cell malignancies.
You may also be interested in...
Did MEI/Kyowa Kirin Beat The PI3K Tolerability Trap?
PI3K-delta inhibitors have often suffered from safety and tolerability issues, but Phase II data show higher efficacy and lower discontinuation rates for zandelisib than others in the class.
Deal Watch: Alnylam/Dicerna Pact Addresses IP Questions Around Primary Hyperoxaluria Programs
The two RNAi firms cross-license IP from their PH programs, while also partnering on a rare liver disease candidate. GSK invests $250m in Vir and will help to advance its antibody candidates for COVID-19.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: Pfizer to boost migraine presence via M&A; Roche’s immunotherapy ambitions take a hit; Biogen’s CEO search gets more complicated; Stoffels lays out new strategy for Galapagos; and mixed results for Japanese majors.